Bicycle Therapeutics (BCYC) vs Scribe Therapeutics (SCTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Scribe Therapeutics is the larger company by market cap ($364.1 million vs $266.7 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCYC | SCTX |
|---|---|---|
| Share price | $3.81 | $19.23 |
| Market cap | $266.67M | $364.06M |
| 1-day change | +2.14% | +9.45% |
| YTD return | -46.19% | — |
| 1-year return | -53.87% | — |
| 5-year return | -93.57% | — |
| EPS (TTM) | $-2.73 | $-3.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.10 | $39.60 |
| 52-week low | $3.33 | $13.50 |
| Distance from 52-week high | -58.13% | -51.44% |
| Analyst consensus | none | none |
| Avg. price target upside | +149.34% | +196.41% |
| Average volume | 387.29K | 357.40K |
| Shares outstanding | 50.55M | 18.93M |
| Employees | 288 | 82 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Bicycle Therapeutics
BCYC stock →Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing.
Health Care · Biotechnology: Pharmaceutical Preparations · 288 employees
About Scribe Therapeutics
SCTX stock →Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 82 employees
BCYC vs SCTX FAQ
Which is bigger, Bicycle Therapeutics or Scribe Therapeutics?
Scribe Therapeutics (SCTX) is larger, with a market capitalization of $364.06M compared with $266.67M for Bicycle Therapeutics (BCYC).
Are Bicycle Therapeutics and Scribe Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Bicycle Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for Scribe Therapeutics.